Dihexa is a potent nootropic peptide studied for HGF/c-Met potentiation, synaptogenesis, and neuroplasticity. Physician-reviewed. Prescription required.
Dihexa is a small synthetic peptide derived from a fragment of Hepatocyte Growth Factor, engineered to cross the blood-brain barrier efficiently. Its mechanisms are centered on promoting synaptogenesis, neuroplasticity, and neuroprotection.
Dihexa has been estimated to be up to a million times more potent than BDNF in promoting synaptogenesis in preclinical models. It is one of the most mechanistically compelling cognitive compounds currently under investigation, though human clinical data remains limited. Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Biological Effect |
|---|---|
| HGF/c-Met potentiation | Enhanced neuroplasticity and synaptogenesis |
| Synaptic protein upregulation | Increased synapse formation |
| PI3K/AKT & MAPK/ERK activation | Cell survival and growth |
| Modulation of neurotrophic factors | Elevated BDNF |
| Enhanced neural network connectivity | Improved learning/memory |
| Increased neurogenesis (preclinical) | Potential regeneration |
Your physician will determine eligibility based on your complete health intake. The following profiles are commonly associated with Dihexa protocol candidates in clinical practice:
Cognitive Decline
Individuals with physician-confirmed cognitive decline where synaptogenesis support may be clinically relevant.
Neuroplasticity Enhancement
Individuals pursuing physician-supervised neuroplasticity optimization.
Memory & Learning
Individuals with memory or executive function concerns seeking advanced nootropic support.
Advanced Cognitive Protocol
Individuals with existing cognitive protocols adding physician-reviewed Dihexa.
Determine your candidacy
A physician will review your intake and make eligibility determination within 24–48 hours.
All outcome language below reflects what has been observed in clinical and preclinical settings. Individual outcomes may differ significantly. These are not guarantees.
Dosing is determined individually by your assigned physician. The following represents typical ranges discussed in clinical literature. Do not self-administer or adjust dosing without physician guidance.
Typical Range
Physician-determined
Administration
Topical, oral, or subcutaneous (physician-determined)
Duration
Physician-determined cycles
Frequency
Physician-determined
These ranges are indicative only. Your physician will prescribe the specific dose and schedule appropriate for your clinical profile.
Physician consultation — Virtual intake review and protocol consultation with your assigned NP/MD
Valid prescription — Issued by your attending physician upon protocol approval
Pharmacy-dispensed compound — Dispensed by our licensed 503A compounding pharmacy partner
Follow-up check-in — Physician review at protocol midpoint; reorder pathway established
Your physician will review your complete health history before determining eligibility. The following are commonly reviewed clinical considerations.
Begin your Dihexa protocol.
Complete your intake. Physician review within 24–48 hours.
Physician-reviewed. Pharmacy-dispensed. Prescription required before any order is fulfilled.
Prescription required. Results may vary. Individual outcomes may differ.
Dihexa is a nootropic peptide studied for cognitive enhancement, neuroregeneration, and potential applications in neurodegenerative disease. It is used to support memory, learning, and brain repair.
Dihexa binds hepatocyte growth factor (HGF) and activates its receptor c-Met, which promotes synaptogenesis — the formation of new neural connections critical for learning and memory.
Verum Health offers Dihexa as a nasal spray for convenient, rapid CNS delivery, bypassing the blood-brain barrier efficiently.
Some patients report improved cognitive clarity and focus within days of starting. More significant neuroregeneration and memory improvements typically develop over weeks to months of consistent use.